Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lusvertikimab - OSE Immunotherapeutics

Next Previous
Search
Drug Profile

Lusvertikimab - OSE Immunotherapeutics

Alternative Names: Anti CD127 monoclonal antibody - OSE Immunotherapeutics; Anti interleukin-7 receptor-α monoclonal antibody - OSE Immunotherapeutics; Effi-7; IL-7 receptor alpha antagonist - OSE Immunotherapeutics; OSE-127; S-95011

Latest Information Update: 25 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Effimune
  • Developer OSE Immunotherapeutics; Servier
  • Class Anti-inflammatories; Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Interleukin 7 receptor alpha subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ulcerative colitis
  • Preclinical Precursor cell lymphoblastic leukaemia-lymphoma
  • Discontinued Crohn's disease; Sjogren's syndrome; Transplant rejection

Most Recent Events

  • 24 Feb 2025 Efficacy and adverse events data from a phase II CoTikiS trial in Ulcerative colitis released by OSE Immunotherapeutics
  • 07 Dec 2024 Pharmacodynamics and adverse events data from a preclinical study in Precursor-cell lymphoblastic leukaemia-lymphoma presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
  • 24 Jul 2024 Efficacy and adverse events data from a phase II trial in Ulcerative colitis released by OSE Immunotherapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top